83-2270-87 KRIBIOLISA Anti-Cetuximab (ERBITUX) ELISA 1 x 96 wells KBI2018

  • 冷蔵
  • 劇物

  • 【試薬に関するお問合せ】
  • アズワン株式会社 試薬グループ
  • TEL:06-6447-8641
  • FAX:06-6447-8642
  • E-mail:[email protected]


  • Description:Enzyme Immunoassay for the quantitative determination of AntiCetuximab in serum, plasma and cell culture supernatant.
  • Cetuximab is an epidermal growth factor receptor (EGFR) inhibitor used for the treatment of metastatic colorectal cancer, metastatic non-small cell lung cancer and head and neck cancer.
  • Cetuximab is a chimeric (mouse/human) monoclonal antibody given by intravenous infusion that is distributed under the trade name Erbitux in the U.S.
  • and Canada by the drug company Bristol-Myers Squibb and outside the U.S.
  • and Canada by the drug company Merck KGaA.
  • In Japan, Merck KGaA, Bristol-Myers Squibb and Eli Lilly have a codistribution.
  • In July 2009, the FDA approved Cetuximab (Erbitux) for treatment of colon cancer with wild-type KRAS, since it had little or no effect in colorectal tumors harboring a KRAS mutation (this also applied to the EGFR antibody panitumumab).Anti-Drug Antibodies (ADA) may induce unwanted side effects in biopharmaceuticals.
  • Hence, ADA has been subjected to increase in scrutiny by the regulatory authorities using immunogenicity safety studies.
  • ADA has been observed in pre-clinical and clinical studies, resulting in significant changes in toxicology, pharmacokinetics and efficacy.
  • These effects result from the generation of drug-induced (neutralizing) autoantibodies against Cetuximab and can be responsible for allergic reaction, or even
  • anaphylactic shock.
  • This ELISA kit detects antibodies for Anti-Cetuximab and may be used for monitoring immunogenicity.
  • Krishgen PK kits, developed using the innovator drug as calibrator, are used for the quantitation of serum protein drug levels, and can be used for biosimilar and generics research as well.
  • About the kit:
  • - Uses anti-idiotypic antibodies sourced from our vendor partner in the US, which ensures higher specificity, and low cross reactivity.
  • - Recovery rates are between 85 - 115%
  • - Ready to use with a standard protocol with break-apart pre-coated wells
  • - Validated as per US FDA guidelines for Bioassays
  • - Optimized for matrix effects to ensure higher sensitivity.
  • - Shelf life: 1 year
  • The method employs the quantitative sandwich enzyme immunoassay technique.
  • Cetuximab is pre-coated onto microwells.
  • Samples and standards are pipetted into microwells and antibodies to Cetuximab present in the sample are bound by the capture antibody.
  • Then, a HRP (horseradish peroxidase) conjugated Cetuximab is pipetted and incubated.
  • After washing microwells in order to remove any non-specific binding, the ready to use substrate solution (TMB) is added to microwells and color develops proportionally to the
  • amount of Anti-Cetuximab in the sample.
  • Color development is then stopped by addition of stop solution.
  • Absorbance is measured at 450 nm.


  • サイズ:1 x 96 wells
  • Reactivity:Human
  • アプリケーション:ELISA,Immunoassay
  • Sensitivity:10 ng/ml
  • Calibration Range:0 ng/ml - 640 ng/ml
  • サンプルタイプ:Serum and Plasma
  • データシート:https://krishgen.com/upload/datasheets/KBI2018-Anti-Cetuximab-IFU-ver1.0-CE-mlang.pdf
  • 測定方法:Colorimetric, 450nm
  • この商品は法規制を確認しておりません。(法規制によって販売できない場合もございます)

アズワン品番 83-2270-87
型番 KBI2018
入り数 1個
標準価格 191,000円(税抜)
アズワン在庫 [?]
サプライヤ在庫 [?]